Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease

2025

JAMA Neurol. 2025 Aug 25:e252974. doi: 10.1001/jamaneurol.2025.2974. Online ahead of print. PMID: 40853684

Insel PS, Mattsson-Carlgren N, Langford O, Caruso VM, Leuzy A, Young CB, Boxer A, Aisen PS, Sperling RA, Mormino EC, Donohue MC.

JAMA Neurol. 2025 Aug 25:e252974. doi: 10.1001/jamaneurol.2025.2974. Online ahead of print. PMID: 40853684

2025 Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers
2025 Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease
2025 Predictive Value of Plasma Biomarkers in Tau-PET Transitions
2025 CSF markers of neuroinflammation, synaptic dysfunction and [18F]DOPA-PET in Parkinson’s disease
2025 Hemispheric asymmetry of tau pathology is related to asymmetric amyloid deposition in Alzheimer’s Disease
2025 Evaluation of a Sensitive Visual Read Algorithm for Assessing 3R/4R Tau PET Images
2025 Association of plasma Alzheimer’s disease biomarkers with cognitive decline in cognitively unimpaired individuals
2025 Plasma tau biomarkers for biological staging of Alzheimer’s disease
2025 Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease
2025 Olfactory dysfunction and amyloid-positivity in Parkinson’s disease-longitudinal analysis of cognitive decline and cerebrospinal fluid markers
2025 Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease
2025 Tau, atrophy, and domain-specific cognitive impairment in typical Alzheimer’s disease
2025 Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification
2025 Modernizing diagnosis of Alzheimer’s disease: A review of global trends and Asia-specific perspectives
2025 Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease